● Project Team Leader for programs in multiple programs directed against cardiovascular disease, pain, and neurodegenerative disease ● Leadership team member for CCT (Chemistry, Characterization and Technology) organization spanning Amgen sites in Cambridge, South San Francisco, and Thousand Oaks● Significantly involved in external outreach and ventures. Member of Amgen Ventures Seed Fund SAB and Amgen’s LabCentral Advisory Committee (decision-making body for award of “Golden Tickets”)● Provided direction and development to a group of 11-16 medicinal chemist reports

● Directed and developed group of reports averaging 16 medicinal chemists (range 7 – 32)● Mentored chemistry team leads to successfully deliver two small molecule protein-protein interaction inhibitors to clinical trials in oncology● Chemistry team lead on APJ agonist program that delivered AMG 986 (evaluated in Phase I clinical trials)● Participated in evaluation of numerous in-licensing opportunities which resulted in two consumnated deals involving compound licensing and active research collaborations for further discovery and development

● Chemistry lead for GPR40 (aka FFA1) program. Designed and synthesized the GPR40 agonist later designated AMG 837, which was evaluated in Phase I clinical trials● Chemistry lead for GPR142 program involving a research collaboration with Daiichi-Sankyo in Japan

● Chemistry lead for GPR40 (aka FFA1) program. ● Designed and synthesized the GPR40 agonist eventually designated AMG 837, which was evaluated in Phase I clinical trials● Chemistry lead for GPR142 program involving a research collaboration with Daiichi-Sankyo in Japan

● Chemistry team member for PPAR-gamma program which was run in collaboration with Japan Tobacco.● Actively involved in identification and eventual delivery of clinical candidate T131 (later AMG 131) which was outlicensed and eventually evaluated in a Phase II clinical trial (as INT131).

● Designed and synthesized T607, a potent and highly selective covalent modifier of beta-tubulin. T607 was advanced to the clinic and evaluated in Phase II trials. Sole inventor on the composition-of-matter patent.